Startups and venture capital
Biograil raises €20 million to advance oral alternative to injectable drugs
The Copenhagen biotech plans to use the funding to prepare its BIONDD oral drug-delivery technology for Phase 1 clinical studies, including non-clinical GLP studies and manufacturing preparations.